| This week's sponsor is Premier Research. | |  | iRECIST: The Future of Solid Tumor Evaluation?
The iRECIST guidance on solid tumor response focuses new attention on standardizing and validating immune response criteria. Will it be the new standard for clinical trials? See what our experts think. Premier Research. It's what we do. Best. |
Featured Story | | | Wednesday, October 4, 2017 Just a few months after Fierce 15 winner CytomX signed a major $3.6 billion biobucks deal with Bristol-Myers Squibb, the biotech is at it again, this time with Amgen. |
|
|
| This week's sponsor is Deloitte. | |  | |
Top Stories Wednesday, October 4, 2017 The immuno-oncology sector has a new player. Massachusetts startup Palleon Pharmaceuticals has raised $47.6 million to fund the development of drugs that target sugar-sensing molecules on the surfaces of cells. Wednesday, October 4, 2017 A second phase 3 trial of Motif Bio’s antibiotic iclaprim has hit its primary endpoint. The data tee Motif Bio up to file for approval of a drug that was knocked back by the FDA in 2009 and almost sunk the biotech 12 months ago. Thursday, September 28, 2017 Learn how one company sought support at multiple junctures—from manufacturing to biomarker evaluation to market access—to enable a faster and more effective launch of their new programmed death receptor-1 (PD-1)-blocking antibody. Wednesday, October 4, 2017 Immatics has raised $58 million (€49 million) to push its cancer immunotherapies deeper into the clinic. The German T-cell specialist turned to its existing investors and new partner Amgen to put together the round, which brings its amount raised to date up toward €200 million. Wednesday, October 4, 2017 Catabasis Pharmaceuticals is looking to test its experimental Duchenne drug edasalonexent in a late-stage trial after posting the last of the data from its midstage work. Wednesday, October 4, 2017 Thync, which markets wearables that help users sleep better or relax, reported the first effective use of bioelectronics to treat psoriasis in a pilot study. The noninvasive therapy “significantly” reduced psoriasis symptoms and could fill a gap in psoriasis treatment. Wednesday, October 4, 2017 Mylan’s long been frustrated by a pair of delays for high-profile generic products. But on Tuesday evening, it picked up an approval for one of them—and it came at Teva’s expense. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Sponsored by: Veeva Systems The 2017 Unified Clinical Operations Survey finds that 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
